Bharat Biotech cuts vaccine price for states to Rs 400 per dose

Bharat Biotech Covaxin
Covaxin is being administered in India in clinical trial mode as part of the nation-wide vaccination programme launched for healthcare workers on January 16. Image courtesy: IANS

New Delhi: Bharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine 'Covaxin' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600.

This follows a widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.

"Recognising the enormous challenges in the public healthcare system, we have made Covaxin available to state governments at a price of 400/ dose", Bharat Biotech said in its announcement.

The company is deeply concerned with the critical pandemic circumstances that India is facing at this time, it added.

Serum Institute of India (SII) had on Wednesday slashed the price of its COVID-19 vaccine 'Covishield' to Rs 300 per dose from the earlier Rs 400 for state governments.

The comments posted here/below/in the given space are not on behalf of Onmanorama. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.